NervGen Pharma Corp. (NGEN) Income Statement

NASDAQ: NGENRevenue, profits, margins and EPS over 9 years.

NGEN 2025 at a glance

Fiscal year ended December 31, 2025 · Canadian dollars
Research & development−11.2%
C$13.9M
2025 · hover or tap a bar for each year
2018: C$777,9272019: C$6.6M (+751.4%)2020: C$6.1M (−7.3%)2021: C$6.9M (+12.1%)2022: C$16.4M (+138.6%)2023: C$8.0M (−51.3%)2024: C$15.7M (+95.7%)2025: C$13.9M (−11.2%)
20172025
Operating expenses+1.0%
C$25.1M
2025 · hover or tap a bar for each year
2017: C$11,9852018: C$1.3M (+11,034.6%)2019: C$10.1M (+656.4%)2020: C$11.2M (+10.8%)2021: C$12.9M (+15.1%)2022: C$22.7M (+76.5%)2023: C$17.6M (−22.3%)2024: C$24.8M (+40.8%)2025: C$25.1M (+1.0%)
20172025
Operating income
−C$25.1M
2025 · hover or tap a bar for each year
2017: −C$11,9852018: −C$1.4M2019: −C$10.1M2020: −C$11.2M2021: −C$12.9M2022: −C$22.8M2023: −C$17.8M2024: −C$24.9M2025: −C$25.1M
20172025
Net income
−C$44.1M
2025 · hover or tap a bar for each year
2017: −C$11,9852018: −C$1.4M2019: −C$10.0M2020: −C$11.2M2021: −C$12.8M2022: −C$20.5M2023: −C$22.4M2024: −C$24.0M2025: −C$44.1M
20172025

NGEN revenue and net income

RevenueNet incomeNet margin (right axis)

NGEN growth rates

to 2025
1 year3 years5 years10 years
Revenue————
Operating income————
Net income————

1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.

NGEN income statement in Canadian dollars

202520242023202220212020201920182017
RevenueC$0C$0C$0C$0C$0C$0C$0C$0C$0
Cost of revenue—C$83,741C$145,014C$114,100C$42,950C$39,733C$39,262C$19,699—
Gross profit—−C$83,741−C$145,014−C$114,100−C$42,950−C$39,733−C$39,262−C$19,699—
Research & developmentC$13.9MC$15.7MC$8.0MC$16.4MC$6.9MC$6.1MC$6.6MC$777,927—
Sales, general & adminC$11.2MC$9.3MC$9.6MC$6.3M—————
Total operating expensesC$25.1MC$24.8MC$17.6MC$22.7MC$12.9MC$11.2MC$10.1MC$1.3MC$11,985
Operating income−C$25.1M−C$24.9M−C$17.8M−C$22.8M−C$12.9M−C$11.2M−C$10.1M−C$1.4M−C$11,985
Interest incomeC$333,415C$812,617C$550,074C$201,396—————
Interest expense——C$0C$510,072—————
Income before taxes−C$44.1M−C$24.0M−C$22.4M−C$20.5M−C$12.8M−C$11.2M−C$10.0M−C$1.4M−C$11,985
Net income−C$44.1M−C$24.0M−C$22.4M−C$20.5M−C$12.8M−C$11.2M−C$10.0M−C$1.4M−C$11,985
EBITDA−C$5.7M−C$23.9M−C$22.2M−C$19.9M−C$12.8M−C$11.2M−C$10.0M−C$1.3M−C$11,985

Quarterly columns are labeled by the month the quarter ended. Figures in Canadian dollars as reported in NGEN's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.

NGEN financial results

NervGen Pharma reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of C$44.1 million. Figures are in Canadian dollars, the currency of its financial statements.

See the NGEN stock overview for the latest quote and news, or the NGEN chart for price history and technical indicators.

NGEN income statement FAQ

Does NervGen Pharma have revenue?

NervGen Pharma reported no revenue for fiscal year 2025, which ended on December 31, 2025.

Is NervGen Pharma profitable?

No. NervGen Pharma reported a net loss of C$44.1 million in fiscal 2025.

How much does NervGen Pharma spend on research and development?

NervGen Pharma spent C$13.9 million on research and development in fiscal 2025.

When will NervGen Pharma report its next earnings?

NervGen Pharma is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.

When does NervGen Pharma's fiscal year end?

NervGen Pharma's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.

Biotechnology income statements